Trials / Completed
CompletedNCT01828593
Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy
Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Study Evaluating the Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in HIV+ Subjects With HIV-associated Enteropathy.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Entera Health, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g twice a day (BID) and SBI 5.0 g versus placebo on supporting nutrient absorption in HIV+ subjects with HIV-associated enteropathy.
Detailed description
This study is evaluating the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5g BID and SBI 5.0g compared to placebo for 6 months on gastrointestinal symptoms, nutritional status and quality of life in HIV+ subjects with HIV-associated enteropathy. In addition, the effects of SBI on pro-inflammatory intestinal microbial populations, bacterial translocation, intestinal barrier function, and systemic immune activation will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Serum-derived bovine immunoglobulin protein isolate (SBI) | SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. |
| OTHER | Placebo | Matching placebo |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-01-01
- Completion
- 2014-09-01
- First posted
- 2013-04-10
- Last updated
- 2017-06-21
- Results posted
- 2016-03-08
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01828593. Inclusion in this directory is not an endorsement.